Chicago Equity Partners LLC decreased its position in Cummins (NYSE:CMI) by 9.1% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 35,290 shares of the company’s stock after selling 3,515 shares during the period. Chicago Equity Partners LLC’s holdings in Cummins were worth $5,720,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Advisor Partners LLC boosted its holdings in shares of Cummins by 8.1% in the fourth quarter. Advisor Partners LLC now owns 3,596 shares of the company’s stock valued at $680,000 after purchasing an additional 269 shares during the period. Parallel Advisors LLC boosted its holdings in shares of Cummins by 6.4% in the fourth quarter. Parallel Advisors LLC now owns 5,004 shares of the company’s stock valued at $884,000 after purchasing an additional 303 shares during the period. Baird Financial Group Inc. boosted its holdings in shares of Cummins by 1.1% in the fourth quarter. Baird Financial Group Inc. now owns 28,069 shares of the company’s stock valued at $4,958,000 after purchasing an additional 310 shares during the period. Jacobs & Co. CA boosted its holdings in shares of Cummins by 1.3% in the fourth quarter. Jacobs & Co. CA now owns 25,673 shares of the company’s stock valued at $4,483,000 after purchasing an additional 330 shares during the period. Finally, Blue Chip Partners Inc. boosted its holdings in shares of Cummins by 9.2% in the fourth quarter. Blue Chip Partners Inc. now owns 4,179 shares of the company’s stock valued at $738,000 after purchasing an additional 353 shares during the period. Hedge funds and other institutional investors own 83.40% of the company’s stock.
Top Blue Chip Stocks To Own For 2019: Athene Holding Ltd. (ATH)
Advisors' Opinion:- [By Stephan Byrd]
Wells Fargo & Co set a $65.00 price target on Athene (NYSE:ATH) in a research note released on Monday. The firm currently has a buy rating on the insurance provider’s stock.
- [By Stephan Byrd]
Athene Holding Ltd (NYSE:ATH) insider Grant Kvalheim sold 2,505 shares of the company’s stock in a transaction on Thursday, August 23rd. The shares were sold at an average price of $50.01, for a total value of $125,275.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
- [By Stephan Byrd]
Athene Holding Ltd (NYSE:ATH) has received an average rating of “Buy” from the sixteen ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have given a hold rating and ten have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $62.10.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on Athene (ATH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
Get a free copy of the Zacks research report on Athene (ATH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top Blue Chip Stocks To Own For 2019: Anixter International Inc.(AXE)
Advisors' Opinion:- [By Stephan Byrd]
TheStreet upgraded shares of Anixter International (NYSE:AXE) from a c+ rating to a b rating in a report issued on Wednesday morning.
Several other equities analysts also recently commented on the stock. ValuEngine downgraded shares of Anixter International from a sell rating to a strong sell rating in a research note on Tuesday. Zacks Investment Research downgraded shares of Anixter International from a strong-buy rating to a hold rating in a research note on Tuesday, September 25th. Finally, Longbow Research upgraded shares of Anixter International from a neutral rating to a buy rating in a research note on Friday, July 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. Anixter International has a consensus rating of Hold and an average target price of $85.50.
- [By Shane Hupp]
Strs Ohio boosted its position in Anixter International Inc. (NYSE:AXE) by 15.4% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 18,700 shares of the technology company’s stock after acquiring an additional 2,500 shares during the period. Strs Ohio’s holdings in Anixter International were worth $1,183,000 as of its most recent SEC filing.
Top Blue Chip Stocks To Own For 2019: Cara Therapeutics, Inc.(CARA)
Advisors' Opinion:- [By Stephan Byrd]
Get a free copy of the Zacks research report on Cara Therapeutics (CARA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Get a free copy of the Zacks research report on Cara Therapeutics (CARA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Sean Williams]
Among the so-called "marijuana drug developers," none logged a more impressive quarter than Cara Therapeutics (NASDAQ:CARA). Shares of the Connecticut-based company soared almost 55%, with most of that run coming in the final week of the quarter.
- [By Keith Speights]
Cara Therapeutics (NASDAQ:CARA) was a highflier one year ago. But then the biotech announced disappointing results in June 2017 for its lead candidate, CR845, in a phase 2b study targeting treatment of pain in patients with osteoarthritis (OA) of the knee or hip. Since then, Cara stock is down more than 50%.
- [By Todd Campbell]
Cara Therapeutics' (NASDAQ:CARA) stock has been on a tear following news that Vifor Fresenius Medical Care Renal Pharma Ltd. licensed certain ex-U.S. rights to Korsuva, Cara Therapeutics' treatment for chronic kidney disease-associated itching in dialysis patients. Since the news was reported, Cara Therapeutics shares have risen from less than $12 per share to over $17 per share, including a gain of as much as 12.5% on Friday.
- [By Maxx Chatsko]
Shares of Cara Therapeutics (NASDAQ:CARA) jumped more than 12% in August, according to data from S&P Global Market Intelligence. The small-cap pharma company announced second-quarter and first-half 2018 earnings results and said a crucial phase 3 trial had begun for its lead drug candidate, difelikefalin.
Top Blue Chip Stocks To Own For 2019: The Kraft Heinz Company(KHC)
Advisors' Opinion:- [By Paul Ausick]
The Kraft Heinz Co. (NASDAQ: KHC) fell about 7% Friday to post a new 52-week low of $67.65 after closing at $72.71 on Thursday. The 52-week high is $97.77. Volume of about 12.8 million was more than three times the daily average. The food processing company reported poor earnings this morning and suggested that sales could get worse as competition increases. https://247wallst.com/consumer-products/2018/02/16/how-kraft-heinz-earnings-fell-short/
- [By Billy Duberstein]
What to do about Kraft-Heinz (NASDAQ:KHC)? One of Berkshire Hathaway's larger holdings (Berkshire owns roughly 26.7% of shares outstanding, controlling the company in tandem with Brazilian investment firm 3G Capital), Kraft's stock has tumbled roughly 28% in 2018, as the consumer packaged foods industry ("CPG") has come under pressure.
- [By Money Morning Staff Reports]
Finally, J.M. Smucker Co. (NYSE: SJM) has hiked its dividend from $0.78 to $0.85 per share. That's a 9% bump and represents the 17th year in a row that the company has hiked its dividend. The company is also starting to look like a potential takeover target for firms like Kraft-Heinz Co. (NYSE: KHC). SJM is also in our "Buy Zone."
No comments:
Post a Comment